Patents Examined by Lance W Rider
  • Patent number: 10750729
    Abstract: A method for allowing an animal to develop atrioventricular block, the method including: administering an immune regulator targeting a sphingosine-1-phosphate receptor to an animal selected from a pig, a monkey and a guinea pig.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: August 25, 2020
    Assignee: TOHO UNIVERSITY
    Inventor: Atsushi Sugiyama
  • Patent number: 10744213
    Abstract: The present invention discloses fluorescent compounds and a method for their use for selective imaging of blood vessels and blood flow. By applying these fluorescent compounds and the imaging process to a zebrafish model, the present invention further provides methods and procedures for the discovery, selection, and characterization of pro- and anti-angiogenic agents.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: August 18, 2020
    Assignee: COLOSSUS BIOPHARMA CONSULTANTS COMPANY, LIMITED
    Inventor: Jose Mendoza
  • Patent number: 10729658
    Abstract: The present invention relates to a process for the production of an abuse-proofed dosage form containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer (C) with a breaking strength of at least 500 N, wherein the formulation mixture is combined with a solvent for the polymer (C) at least in quantities such that the formulation mixture is at least uniformly moistened, the at least moistened composition is optionally divided into sub-portions, dried and shaped to yield the dosage form.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: August 4, 2020
    Assignee: GRÜNENTHAL GMBH
    Inventors: Elisabeth Arkenau-Marić, Johannes Bartholomäus
  • Patent number: 10682421
    Abstract: There is disclosed a composition in the form of a nanoparticle. The nanoparticle composition has a diameter from 5 to 500 nanometers. The nanoparticle composition has i) a central core portion including magnetic Fe3O4 nanoparticles adapted to act as a heat source when subjected to a magnetic field and a chemotherapeutic agent configured to treat cancer tissues, ii)—a shell portion including a shell member encapsulating said core portion, and iii)—antibodies configured to target cancer stem cells and adhered to surface of said shell member. The chemotherapeutic agent is a heat shock protein inhibitor and is releasable on activation of the heat source due to the magnetic field, and the shell member is made of silica or a silica based material.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: June 16, 2020
    Assignee: CITY UNIVERSITY OF HONG KONG
    Inventors: Mengsu Yang, Dandan Liu
  • Patent number: 10670581
    Abstract: The present invention provides oxygenized nanobubbles and their uses in imaging and cancer treatment when combined with therapeutic drugs and precise ultrasound beam steering.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: June 2, 2020
    Assignee: Purdue Research Foundation
    Inventors: Joseph Irudayaraj, Pushpak Bhandari
  • Patent number: 10660835
    Abstract: A method directed to a hair soaking treatment for frizz reduction comprising immersion of consumer hair into an aqueous composition is disclosed. A method for hair frizz reduction wherein hair is soaked for at least about 2 minutes in an aqueous composition having a viscosity of less than about 1000 cP comprising from about 0.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: May 26, 2020
    Assignee: The Procter and Gamble Company
    Inventors: Supriya Punyani, Jennifer Mary Marsh, James Charles Dunbar, Curtis Bobby Motley, Lisa Jo Bartz, Erica Vencil Buckner
  • Patent number: 10568970
    Abstract: Provided herein are theranostic compositions comprising a Janus nanoparticle-coated microbubble that are useful for imaging (e.g., MRI, or ultrasound) and for delivering a therapeutic or bioactive agent (e.g., nucleic acid(s), drugs, etc), among other uses.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: February 25, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Joyce Y. Wong, Ragnhild D. Whitaker, Nelson Ruiz-Opazo, Victoria L. M. Herrera
  • Patent number: 10562920
    Abstract: The present invention concerns heterometallic metallacrown compounds incorporating Ga(III) and Ln(III) cations, with a templating ligand such as salicylhydroxamic acid or derivatives thereof, wherein said metallacrown contains at least one repeating [—Ga—N—O—] sub-unit where the N—O derives from the templating ligand.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: February 18, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Evan R. Trivedi, Vincent L. Pecoraro, Svetlana V. Eliseeva, Stépane Petoud, Chun Y. Chow, Tu Ngoc Nguyen, Jacob Charles Lutter, Ivana Martinic
  • Patent number: 10525150
    Abstract: A contrast agent having a contrast protein have contrast properties and at least one targeting moiety, wherein the at least one targeting moiety is operatively linked to or incorporated within the contrast protein. Methods for targeting contrast agents and for preparing such agents are included.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: January 7, 2020
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Jenny J. Yang, Zhi-Ren Liu
  • Patent number: 10441582
    Abstract: Disclosed herein is an injectable anticancer composition for local administration, which contains a suspension of quinine hydrochloride. The anticancer composition for local administration according to the present invention shows an IC50 value against MKN-45 cells, which is about 10 times lower than Paclitaxel, as determined by an MTT assay in vitro, suggesting that the anticancer composition has an excellent cytotoxic effect. The anticancer composition can be administered as a safe anticancer agent in clinical applications, and also shows an anticancer effect by inducing the necrosis and detachment of solid cancer cells. Particularly, the anticancer composition has an anticancer mechanism by which the composition acts locally in a tumor tissue administered with the composition and shows a rapid antitumor effect (1-2 weeks after administration).
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: October 15, 2019
    Inventor: Oh Young Yeo
  • Patent number: 10434193
    Abstract: The present invention relates to a composition for use as a contrast agent in medical imaging. The composition comprises a metal ion containing compound comprises at least one metal ion adapted to bind with one or more metal ion chelating agents; wherein said one or more metal ion chelating agents comprise at least one first chelating agent adapted to target a region of interest being imaged, and at least one second chelating agent having at least one functional group adapted to dissociate in an aqueous medium to thereby allow or enhance contrast of the region of interest under the medical imaging. The present invention further relates to a diagnostic agent for use in amyloid (A?) protein detection under magnetic resonance imaging (MRI) comprising the above described composition; and a method of preparing thereof.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: October 8, 2019
    Assignee: Jacobson Research Laboratory Limited
    Inventors: Connie Sau-Kuen Kwok, Kwok Kin Cheng
  • Patent number: 10406088
    Abstract: Provided is a topical formulation comprising (1) three or more of the following four components a through d, or (2) component c and one or more of components a, b or d: (a) a skin barrier repair formulation comprising fatty acid, bilayer-stabilizing steroid, and complex lipid (CL), wherein the weight ratio of CL to steroid is from about 1.5:1 to about 8:1, and the weight ration of CL to FA is from about 4:1 to about 1:1, the lipids present in an amount from about 3% wt. to about 10% wt.; (b) a natural moisturizer formulation, wherein the natural moisturizers are urea, urocanic acid, pyrrolidone-5-carboxylic acid, lactic acid or free amino acid; (c) one or more retinoids in an amount from about 0.01% wt. to about 10% wt.; or (d) taurine in an amount from about 0.1% wt. to about 5% wt.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: September 10, 2019
    Assignee: TetraDerm Group LLC
    Inventors: Thomas Sköld, Georgia Levis, Michael J. Burns
  • Patent number: 10383958
    Abstract: Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: August 20, 2019
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Keith L. Black, Julia Ljubimova, Alexander Ljubimov, Eggehard Holler
  • Patent number: 10342881
    Abstract: Nanoparticles for use as magnetic resonance imaging contrast agents are described. The nanoparticles are made up of a polymeric support and a manganese-oxo or manganese-iron-oxo cluster having magnetic properties suitable of a contrast agent. The manganese-oxo clusters may be Mn-12 clusters, which have known characteristics of a single molecule magnet. The polymer support may form a core particle which is coated by the clusters, or the clusters may be dispersed within the polymeric agent.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: July 9, 2019
    Assignee: Georgetown University
    Inventors: Sarah Stoll, Julie Quinn, Edward Van Keuren, Christopher Albanese, Stanley Fricke
  • Patent number: 10232046
    Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: March 19, 2019
    Assignee: Baxter International Inc.
    Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
  • Patent number: 10213421
    Abstract: The present invention relates to pharmaceutical compositions containing one or more compounds of formula 1 wherein R1 is H, C1-6-alkyl, C0-4-alkyl-C3-6-cycloalkyl, C1-6-haloalkyl; R2 is H, C1-6-alkyl; X is an anion selected from the group consisting of chloride or ½ dibenzoyltartrate j is 1 or 2. processes for the preparation thereof, and their use to treat diseases connected with the CCR3 receptor.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: February 26, 2019
    Assignee: Alkahest, Inc.
    Inventors: Alfred Fetscher, Jochen Matthias Scher
  • Patent number: 10195127
    Abstract: The present invention provides a cosmetic composition containing (A) a powder composed of one or more kinds of the N-medium-chain-acyl basic amino acid powder represented by the following formula (I), (B) an inorganic powder, and (C) an oil material: wherein R is a saturated or unsaturated straight hydrocarbon group having 5-9 carbon atoms, and m is an integer of 1-4.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: February 5, 2019
    Assignee: AJINOMOTO CO., INC.
    Inventors: Masayuki Kuramoto, Eiko Oshimura
  • Patent number: 10124068
    Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: November 13, 2018
    Assignee: Baxter International, Inc.
    Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
  • Patent number: 10111961
    Abstract: Microparticles and nanoparticles of hydrophobized proteins and an alpha-cyclodextrin, obtained by auto-association in an aqueous medium, the hydrophobized protein being obtained by grafting of alkyl chains coming from fatty acids, by an acylation reaction. These microparticles and nanoparticles constitute systems used for encapsulation of active substances of interest, in particular in the pharmaceutical field, and the vectorization thereof for therapeutic purposes.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: October 30, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SUD XI
    Inventor: Kawthar Bouchemal
  • Patent number: 10106562
    Abstract: This application relates to a process for making a pharmaceutically acceptable formulation of gadofosveset trisodium monohydrate, wherein the process uses no more than one chromatographic purification for removal of impurities.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 23, 2018
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Tarakeshwar Anklekar, Jan Haller, Nicolas Champion, Franz-Willi Herkenrath